Evelyn P. Whitlock, MD, MPH; Jennifer S. Lin, MD, MCR; Elizabeth Liles, MD; Tracy L. Beil, MS; Rongwei Fu, PhD
Acknowledgment: The authors thank the following peer reviewers for the evidence report (alphabetical)James Allison, MD, Carrie Klabunde, PhD, Ted Levin, MD, Perry Pickhardt, MD, Margaret Piper, PhD, MPH, David Ransohoff, MD, Robert Smith, PhD, and Steve Woolf, MD, MPH; Oregon Evidence-based Practice Center staffKevin Lutz, MA, Taryn Cardenas, BA, Rebecca Newton-Thompson, MD, MPH, Elizabeth O'Connor, PhD, Mark Helfand, MD, MS, MPH, and Daphne Plaut, MLS; and Centers for Disease Control and Prevention staffLaura Seeff, MD.
Grant Support: This study was conducted by the Oregon Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality (contract HHSA-290-2007-10057-I-EPC3, task order 3).
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Reprints are available from the Agency for Healthcare Research and Quality Web site (www.ahrq.gov/clinic/uspstfix.htm).
Current Author Addresses: Drs. Whitlock, Lin, and Liles and Ms. Beil: Kaiser Permanente Center for Health Research, Kaiser Permanente Northwest, 3800 North Interstate Avenue, Portland, OR 97227.
Dr. Fu: Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239.
In 2002, the U.S. Preventive Services Task Force (USPSTF) recommended colorectal cancer screening for adults 50 years of age or older but concluded that evidence was insufficient to prioritize among screening tests or evaluate newer tests, such as computed tomographic (CT) colonography.
To review evidence related to knowledge gaps identified by the 2002 recommendation and to consider community performance of screening endoscopy, including harms.
MEDLINE, Cochrane Library, expert suggestions, and bibliographic reviews.
Eligible studies reported performance of colorectal cancer screening tests or health outcomes in average-risk populations and were at least of fair quality according to design-specific USPSTF criteria, as determined by 2 reviewers.
Two reviewers verified extracted data.
Four fecal immunochemical tests have superior sensitivity (range, 61% to 91%), and some have similar specificity (97% to 98%), to the Hemoccult II fecal occult blood test (Beckman Coulter, Fullerton, California). Tradeoffs between superior sensitivity and reduced specificity occur with high-sensitivity guaiac tests and fecal DNA, with other important uncertainties for fecal DNA. In settings with sufficient quality control, CT colonography is as sensitive as colonoscopy for large adenomas and colorectal cancer. Uncertainties remain for smaller polyps and frequency of colonoscopy referral. We did not find good estimates of community endoscopy accuracy; serious harms occur in 2.8 per 1000 screening colonoscopies and are 10-fold less common with flexible sigmoidoscopy.
The accuracy and harms of screening tests were reviewed after only a single application.
Fecal tests with better sensitivity and similar specificity are reasonable substitutes for traditional fecal occult blood testing, although modeling may be needed to determine all tradeoffs. Computed tomographic colonography seems as likely as colonoscopy to detect lesions 10 mm or greater but may be less sensitive for smaller adenomas. Potential radiation-related harms, the effect of extracolonic findings, and the accuracy of test performance of CT colonography in community settings remain uncertain. Emphasis on quality standards is important for implementing any operator-dependent colorectal cancer screening test.
Analytic framework and key questions (KQs).
KQ1: What is the effectiveness of the following screening methods (alone or in combination) in reducing mortality from colorectal cancer? a. Flexible sigmoidoscopy, b. Colonoscopy, c. Computed tomographic (CT) colonography, d. Fecal screening tests: i. High-sensitivity guaiac fecal occult blood test (FOBTs); ii. Fecal immunochemical test; iii. Fecal DNA test. KQ2a: What are the sensitivity and specificity of 1) colonoscopy and 2) flexible sigmoidoscopy when used to screen for colorectal cancer in the community practice setting? KQ2b: What are the test performance characteristics of 1) CT colonography and 2) fecal screening tests (as listed in KQ1d) for colorectal cancer screening, as compared to an acceptable reference standard? KQ3a: What are age-specific rates of harm from colonoscopy and flexible sigmoidoscopy in the community practice setting? KQ3b: What are the adverse effects of newer tests, including 1) CT colonography and 2) fecal screening tests (as listed in KQ1d)?
Appendix Table 1. Eligibility Criteria for Studies, by Key Question
Appendix Table 2. U.S. Preventive Services Task Force Design-Specific Quality Rating Criteria
Appendix Table 3. SAS Code for the Meta-Analysis of Serious Complications
KQ= key question; SER= standardized evidence review. For list of key questions, see legend for Figure 1.
Table 1. Summary of Newer Fecal Test Studies
Table 2. Accuracy of Computed Tomographic Colonography and Estimated Rates of Referral to Colonoscopy
Appendix Table 4. Extracolonic Findings in Asymptomatic Persons Undergoing Computed Tomographic Colonography
Proportion of total serious complications in colonoscopy studies.
Test for heterogeneity for all studies based on logit of proportions using a random-effects model (P= 0.13).
* 95% CIs are exact confidence intervals.
Proportion of total serious complications in flexible sigmoidoscopy studies.
Test for heterogeneity for all studies based on logit of proportions using a random-effects model (P= 0.26).
Table 3. Summary of Results
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for Colorectal Cancer: A Targeted, Updated Systematic Review for the U.S. Preventive Services Task Force. Ann Intern Med. ;149:638–658. doi: 10.7326/0003-4819-149-9-200811040-00245
Download citation file:
Published: Ann Intern Med. 2008;149(9):638-658.
Cancer Screening/Prevention, Colonoscopy/Sigmoidoscopy, Colorectal Cancer, Gastroenterology/Hepatology, Gastrointestinal Cancer.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use